Abstract: TH-PO356
Sea Moss Supplement-Induced Hyperkalemia with Electrocardiographic (EKG) Changes
Session Information
- Sodium, Potassium, and Volume Disorders: Clinical
October 24, 2024 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Fluid, Electrolytes, and Acid-Base Disorders
- 1102 Fluid, Electrolyte, and Acid-Base Disorders: Clinical
Authors
- Zoma, Marim, Loyola University Chicago Stritch School of Medicine, Chicago, Illinois, United States
- Rochlin, Emma, Loyola University Chicago Stritch School of Medicine, Chicago, Illinois, United States
- Abourahma, Mohammed Ashraf, Loyola University Medical Center, Maywood, Illinois, United States
- Libot, Agnes R., Loyola University Medical Center, Maywood, Illinois, United States
Introduction
Sea Moss is a widely available herbal supplement, gaining popularity for its supposed health and weight loss benefits. It is high in calcium, magnesium, potassium, and iodine. Sea moss has known risks associated with the excessive iodine, particularly for those with thyroid issues. Our patient experienced hyperkalemia after two weeks on a restrictive sea moss diet, indicating possible additional risks of this supplement.
Case Description
A 72-year-old male with a history of hyperthyroidism, HLD, HTN, CKD stage 3A presented to the emergency department with a one-day history of non-bloody emesis, fatigue and dizziness. In an attempt to lose weight, he was participating in a two-week “sea moss” diet consisting of fruit, water, and sea moss supplements. He continued to take his prescribed medications, including amlodipine and losartan.
In the ED, the patient was hypotensive (85/53) and bradycardic (pulse in 40s). Other vital signs remained stable. Physical examination was benign. Labs were notable for: Sodium 130, Potassium 7.1, BUN 54, Cr 4.77 (baseline 1.9), and TSH of 0.26. CBC and troponin levels were within normal limits. The initial EKG displayed peaked T waves and sinus bradycardia, indicative of hyperkalemia. Assessment of renal function showed prerenal AKI, but was otherwise unremarkable.
The patient received a 3L IV fluid bolus, calcium gluconate, insulin, and kayexalate to manage hyperkalemia and stabilize cardiac membranes. Antihypertensive medications were stopped, and the patient was continued on maintenance fluids. After a 4-day hospitalization and fluid-resuscitation, the patient's AKI resolved, potassium levels improved to 4.4, and EKG normalized.
Discussion
This report outlines a case of hyperkalemia with associated arrhythmias provoked by excessive sea moss supplementation in a patient taking losartan. This case highlights the growing trend of supplement usage for health management, often without full awareness of their physiological effects and drug interactions. It's crucial for healthcare providers to proactively inquire about patients' supplement use and prioritize discussions on the associated risks.
Abnormal EKG